[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:gray-zone-lymphoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":22,"states":23},"Gray-Zone Lymphoma",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07283822","Amping up With PemJAK",[11],"Phase 2","RECRUITING","2026-08-26T02:15:03.757872Z","2026-05-05T02:43:29.349629Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT04231877","Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma",[19],"Phase 1","2026-08-03T01:58:01.892442Z","2026-05-05T02:43:28.077600Z",[],[]]